Hospira Japan Receives Approval for New Generic Oncology Products

On August 16, 2015 Hospira Japan Co., Ltd. reported that two new generic oncology drugs have been approved by the Ministry of Health, Labour and Welfare (MHLW) in Japan (Press release, Hospira, AUG 16, 2015, View Source;p=RssLanding&cat=news&id=2079850 [SID:1234507271]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Gemcitabine I.V. lnfusion[Hospira] is the pre-mixed solution and the additional dosage form to Gemcitabine for I.V. lnfusion[Hospira] with freeze-dried formulation. It is expected to contribute to reducing the medical preparation time and the risks of exposure to cytotoxic agents.
Oxaliplatin I.V. lnfusion 200mg/40mL [Hospira] is the additional presentation to the current Oxaliplatin lineup – 50mg/10mL, 100mg/20mL.

We are committed to launching a broad portfolio of high-quality generics in Japan to meet medical needs of patients across the country.

About the Products
[Product name]
Gemcitabine I.V. lnfusion 200mg/5.3mL [Hospira]
Gemcitabine I.V. lnfusion 1g/26.3mL [Hospira]
[Therapeutic category]
Metabolic antagonist malignant tumour drug
[Indications]
Non-small cell lung cancer, pancreatic cancer, biliary tract cancer, uroepithelial cancer, inoperable or recurrent breast cancer, ovarian cancer progressing after chemotherapy, recurrence or refractory malignant lymphoma

[Product name]
Oxaliplatin I.V. lnfusion 200mg/40mL [Hospira]
[Therapeutic category]
Anticancer drug
[Indications]
Unresectable advanced/recurrent colorectal cancer, Supplementary postoperative chemotherapy for colon cancer, Inoperable pancreatic cancer

Hospira Japan has a partnership co-promoting oncology generic products with Mochida Pharmaceuticals in Japan.